Pharmaceutical - Anti-virals, Merck & Co

Filter

Current filters:

Anti-viralsMerck & Co

Popular Filters

1 to 25 of 35 results

Merck Ebola vaccine is well-tolerated by volunteers in early trials

Merck Ebola vaccine is well-tolerated by volunteers in early trials

02-12-2014

The Ebola vaccine developed by pharma giant Merck & Co and NewLink has been well-tolerated by trial volunteers…

Anti-viralsMerck & CoNewLink GeneticsPharmaceuticalResearch

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

11-11-2014

US pharma giant Merck & Co has admitted that interim data from its triple-therapy regimen in hepatitis…

Anti-viralsHCVHepatitis CHepatitis C virusMerck & CoPharmaceuticalResearchsofosbuvirUSA

Bristol-Myers resolves Sustiva patent litigation in USA

Bristol-Myers resolves Sustiva patent litigation in USA

08-10-2014

US pharma major Bristol-Myers Squibb has successfully resolved all outstanding US patent litigation relating…

Anti-viralsAtriplaBristol-Myers SquibbCiplaLegalMerck & CoPatentsPharmaceuticalSustivaUSA

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

12-06-2014

Given the huge potential, and interest in, the hepatitis treatment market, and US pharma giant Merck…

Anti-viralsIdenix PharmaceuticalsMerck & CoMergers & AcquisitionsPharmaceutical

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

07-03-2014

USA pharma giant Merck & Co subsidiary MSD says that in a 96-week, open-label AIDS Clinical Trials Group…

Anti-viralsIsentressMerck & CoPharmaceuticalResearch

Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir

21-02-2014

US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

FDA grants Merck’s hepatitis C treatment breakthrough designation

FDA grants Merck’s hepatitis C treatment breakthrough designation

23-10-2013

US pharma giant Merck & Co has announced that the US Food and Drug Administration has granted MK-5172/MK-8742…

Anti-viralsMerck & CoNorth AmericaPharmaceuticalRegulation

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23-04-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

09-04-2013

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Cytomegalovirus infections market completely controlled by Roche's Valcyte

05-02-2013

The global cytomegalovirus (CMV) infections market has been forecast to increase at a compound annual…

Anti-viralsletermovirMarkets & MarketingMerck & CoPharmaceuticalRocheValcyte

Merck & Co and Gilead highlight new data at international HIV meeting

16-11-2012

US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

Merck & Co in-licenses portfolio targeting HCMV from AiCuris for up to $570 million

16-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide licensing agreement with…

AiCurisAnti-viralsletermovirLicensingMerck & CoPharmaceutical

1 to 25 of 35 results

Back to top